GlobeNewswire by notified

Annual report 2023 confirms positive trend

Share

Copenhagen, April 30, 2024 (GLOBE NEWSWIRE) -- Announcement no. 7-2024


The media tech company Hypefactors presents the annual report for 2023.

Revenue for the period amounted to DKK 11.219M, compared to DKK 9.384M in 2022, corresponding to an increase of 20%. Earnings before interest, tax, depreciation, and amortization (EBTIDA) amounted to DKK 1.974m, compared to 0.333M in 2022, corresponding to an increase of 493%. Hypefactors reached an annual recurring revenue (ARR) of DKK 13.024M per December 31, 2023, (2022: 10.625M) which is an increase over the last twelve months of 23%.

The company has sustained a positive trend and achieved growth in its client base. The principal objective in 2023 was to drive direct sales to enterprise clients, utilizing the full suite of the media intelligence platform. Hypefactors is an innovative technology that utilizes Natural Language Processing (NLP) and AI to provide operational insights on corporate reputation and trust. This technology also makes it effortless for users to measure the impact of their communications and to automate workflows. In 2023, we expanded and further refined the technological assets.

The company will continue to invest in further continued development of AI technology and commercial scaling to ensure long-term ARR growth.

Innovations
Again in 2023, Hypefactors continued to launch major upgrades to its artificial intelligence, increasing the quality of the company’s media insights solution to a level that is unmatched in the industry. The AI technology stack was improved on several dimensions, including the NOI (which is our AI-based NER), the reputation-AI, and the ESG-AI (which can categorize media coverage in all languages along 26 environmental, social and governance dimensions to facilitate ESG sustainability reporting and compliance). Worth mentioning is also the launch of our unique AI solution program for more precise print media processing in media intelligence. It enables Hypefactors to deliver a magnitude larger print coverage than any competitor within media intelligence, and to deliver a superior solution to large enterprises with cross-border media presence.

In October 2022, Hypefactors kicked off a 10-months AI development project named ‘New Print PDF Processing Program’. The special AI effort was backed by the Innovation Fund Denmark and was finalized within the timeline mid 2023. The AIs developed are uniquely superior for its multilingual and multi-modal qualities: It includes an encoder design also found in modern generative AIs like ChatGPT and is combined with computer vision algorithms and an automated reasoning engine also found for development of safety-critical systems such as satellites. It will benefit current and new clients. We further boosted the machine learning operations architecture: Originally designed in 2021, first launched in May 2022, upgraded in December 2022 and again in May 2023, it now enables scaling AI enrichments up to 100 billion machine learning operations per day. Our AIs encompass all the typical traits and benefits of our DNA: Multilingual for more than 100 languages, accelerated for 24/7 billion-scale operation on the world’s media coverage and directly integrated to end-user product features for the benefit of all current and new clients. On December 1, 2023, we launched a new generation of the technology dedicated for sustainability reporting, which takes sustainability intelligence to an unprecedented level of insight.

Annual report
The annual report for 2023 is available for download at www.hypefactors.com/investor

General meeting
The company's annual general meeting will be held on May 30, at 16:00 at Hypefactors' premises, Kronprinsessegade 8B in Copenhagen K.


Important reminder for all shareholders: Last day of trading is May 14

As previously announced, Hypefactors will be delisted from Nasdaq First North Growth Market. A decision that was backed by 98.44% of shareholders vote. All shareholders should be aware that last day of trading will be May 14, 2024. The delisting of the company’s shares from trading on Nasdaq First North Growth Market Denmark will eliminate a formal marketplace for trading the company’s shares. Instead, future transactions involving the company’s stock will occur over the counter. This is expected to reduce the liquidity of the company’s shares further. Consequently, buying and selling company shares may become more challenging, and transactions may require legal support, which the parties involved in any over-the-counter dealings would need to fund independently. A shareholder’s tax status regarding the shares may change, as the shares will no longer be listed on a SME Growth Market. For shareholders to stay updated after the delisting, please check www.hypefactors.com/investor


----

About Hypefactors A/S

Hypefactors is an AI based reputation and corporate trust technology company, providing a tech platform to support better media intelligence and reputation/trust management. Hypefactors combine data, analytics, technology, and tools to provide a unified and easy-to-use experience. With all the tools to automate and ease the work, and all the facts to document the results. In addition to media monitoring across the different media channels, the platform provides access to several facts, incl. automated documentation of the monetary value and quality assessment of each third-party media mention. The platform also contains other time-saving tools such as automatically generated media reports and a mobile app giving access to real-time media mentions. The company is listed at Nasdaq Growth Market in Copenhagen, Denmark.


For more information, please contact:

Casper Janns, CEO: +45 20167481, e-mail:cj@hypefactors.com

Martin Michael Hansen, Chairman of the Board: + 45 20871845, e-mail: mmh@yu.agency

Hypefactors A/S
Kronprinsessegade 8B
1306 Copenhagen K
Denmark
www.hypefactors.com

Certified Adviser
Beierholm Corporate Finance P/S
Østergade 26B
1100 København K
Kim Harpøth Jespersen, Partner, M +4552150243, e-mail: k.jespersen@dk.oaklins.com


Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Constellation Brands to Present at the Bernstein 40th Annual Strategic Decisions Conference on Wednesday, May 29, 202416.5.2024 22:30:20 CEST | Press release

VICTOR, N.Y., May 16, 2024 (GLOBE NEWSWIRE) -- Constellation Brands, Inc. (NYSE: STZ), a leading beverage alcohol company, announced today that Bill Newlands, President and Chief Executive Officer, and Garth Hankinson, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Bernstein 40th Annual Strategic Decisions Conference on Wednesday, May 29, 2024 in New York, NY. The presentation is scheduled to begin at 2:30 p.m. EDT and is expected to cover the company’s strategic business initiatives, financial metrics, and operating performance, as well as outlook for the future. A live, listen-only webcast of the presentation will be available on the company’s investor relations website at ir.cbrands.com under the News & Events section. When the presentation begins, financial information discussed in the presentation, and a reconciliation of reported GAAP financial measures with comparable and other non-GAAP financial measures, will also be available

DBV Technologies Announces Results of its 2024 Combined General Meeting16.5.2024 22:30:00 CEST | Press release

Châtillon, France, May 16, 2024 DBV Technologies Announces Results of its 2024 Combined General Meeting Shareholders approved all proposed resolutions DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the “Company”), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, held its Combined General Meeting (the “General Meeting”). The General Meeting was chaired by Michel de Rosen, Chairman of the Company. The Company’s shareholders approved all resolutions submitted by the Board of Directors. These resolutions and their results are posted on the Investors/Annual General Meetings section of the Company’s website: https://dbv-technologies.com/events/2024-annual-general-meeting/. About DBV Technologies DBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with sign

Clean Motion AB delårsredogörelse för januari-mars 202416.5.2024 22:10:00 CEST | Pressemelding

Elfordonstillverkaren Clean Motion AB presenterar sin delårsrapport för januari-mars 2024. Bolaget redovisar en försäljning på 38 (45) TSEK och ett rörelseresultat exklusive avskrivningar (EBITDA) på -2 949 (-1 825) TSEK. Bolaget meddelar även att ett licensavtal är tecknat för tillverkning av Zbee i Indien samt att deras nya produktionslokal för EVIG i Jonsered nu är godkänd. Sofia Haby, VD kommenterar; ”Vi har jobbat intensivt under kvartalet med både typgodkännande-processen och flytt till nya lokaler. Kvartalet har präglats av de förseningar som vi drabbats av med vårt typgodkännande, vilket förhindrat försäljning i Europa. Jag kan nu med glädje meddela att det mest kritiska testet blev godkänt igår kväll! Under de senaste månaderna har vi jobbat med att färdigställa vår nya produktionslokal i Jonsered. Jag är övertygad om att vi genom att samla alla resurser under ett tak, kommer att åstadkomma stora effektivitetsförbättringar. Teamet har arbetat dedikerat med att säkerställa en s

Galapagos creates new subscription right plans16.5.2024 22:01:00 CEST | Press release

Mechelen, Belgium; 16 May 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 1,614,000 subscription rights under new subscription right plans for the benefit of certain members of the personnel of the company and its subsidiaries. On 16 May 2024, the Board of Directors of Galapagos approved “Subscription Right Plan 2024 BE”, intended for members of personnel of the company, “Subscription Right Plan 2024 RMV,” intended for the employees of its French subsidiary, Galapagos SASU, and “Subscription Right Plan 2024 ROW”, primarily intended for the employees of its other non-Belgian subsidiaries, within the framework of the authorized capital. Under these subscription right plans, 1,614,000 subscription rights were created, subject to acceptances, and offered to the beneficiaries of the plans. The subscription rights have an exercise term of eight years as of the date of the offer and have an exercise price of €

Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH16.5.2024 22:00:00 CEST | Press release

The Data Monitoring Committee recommended to continue the clinical trial without modification of the current protocol, based on the pre-planned review of safety data.The recommendation was based on the unblinded review by the DMC of safety data from more than 900 patients randomized in the main and exploratory cohorts, including more than 360 and 80 patients that have been treated for more than 48 and 72 weeks, respectively.The patient who experienced the adverse event of increased liver test results, which was reported as a SUSAR, has been without clinical symptoms throughout the period of observation and has fully recovered.The DMC review confirms the good safety profile of lanifibranor. Daix (France), Long Island City (New York, United States), May 16, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepa

HiddenA line styled icon from Orion Icon Library.Eye